ClinicalTrials.gg

Program

SYH2069

A development code. Also written as “SYH2069 Injection”, “SYH2069 Injection (group 1)” and “SYH2069 Injection (group 2)”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2, led by CSPC Pharmaceutical Group.

Furthest: phase 2, since Aug 25, 20263 company-led studies, 3 open or runningNext primary completion: Sep 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group33 open or runningphase 2since Aug 25, 2026Jul 14, 2026Sep 28, 2027phase 2 · NCT07796477

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2026First study: phase 1 study in OverweightFirst studyNCT07736391 · 104 enrolled · China
  2. Aug 25, 20262 phase 2 studiesPhase 2 reachedNCT07803991, NCT07796477

Ahead

  1. Sep 28, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07796477
  2. Sep 30, 2027Primary completion: phase 2 study in OverweightNCT07803991

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07803991Overweight · China2Not yet recruitingSep 30, 2027360
NCT07796477Diabetes Mellitus, Type 2 · China2Not yet recruitingSep 28, 2027240
NCT07736391Overweight · China1Active, not recruitingJul 30, 2026104

How it is read

Names in the registry

  • “SYH2069 Injection”, 2 entries
  • “SYH2069 Injection (group 1)”, 1 entry
  • “SYH2069 Injection (group 2)”, 1 entry
  • “SYH2069 Injection (group 3)”, 1 entry
  • “SYH2069 Injection (group 4)”, 1 entry

Codes read as this program: SYH2069.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.